Testosterone Therapy Improves Sexual Function After Radical Prostatectomy

Androgen Replacement in the Prostate Cancer Survivor

Prostate cancer is the most prevalent malignancy among men, and as screening and surgical techniques improve, the population of long-term survivors continues to expand [1]. Many of these men experience symptomatic hypogonadism, which significantly impairs quality of life through fatigue, decreased libido, and adverse metabolic shifts [2]. Despite these symptoms, clinicians often avoid prescribing testosterone replacement therapy due to the long-standing medical consensus that exogenous androgens might stimulate occult malignant cells [3, 4]. While recent meta-analyses of the general population have not found a significant association between testosterone therapy and the development of high-grade prostate cancer, data specifically addressing survivors remain sparse [5, 6]. Consequently, major clinical guidelines continue to list a history of prostate cancer as a contraindication, citing the absence of rigorous, randomized controlled trials in this cohort [7]. A new phase 2 trial now provides evidence regarding the short-term safety and functional benefits of androgen replacement in post-prostatectomy patients, offering a potential pathway to safely manage hypogonadism in this specific population.

Trial Design and Low-Risk Patient Selection

The researchers conducted a randomized, placebo-controlled, double-blind, parallel-group, phase 2 trial at two academic medical centers to evaluate the safety and efficacy of androgen replacement in a specific subset of prostate cancer survivors. The study enrolled men 40 years and older who had previously undergone radical prostatectomy for organ-confined, low-grade prostate cancer. Eligibility was strictly limited to patients with a Gleason score of 6 (3 + 3) or 7 (3 + 4), representing low- to favorable-intermediate-risk disease. Furthermore, participants were required to have maintained an undetectable prostate-specific antigen (PSA) level for at least 2 years following their surgery, ensuring a period of established biochemical stability before initiating therapy. To qualify for the intervention, participants had to demonstrate symptomatic hypogonadism, defined as a mean of two separate morning testosterone levels less than 275 ng/dL accompanied by clinical symptoms of low libido, erectile dysfunction, or fatigue. A total of 136 men were randomized, with 68 assigned to the treatment arm and 68 to the placebo group. The study utilized concealed block randomization (a method that groups participants to ensure balanced sample sizes across arms while keeping the sequence hidden from investigators) and stratified patients by age (40 to 60 years or older than 60 years) and the use of phosphodiesterase-5 inhibitors (PDE5I) to account for these potential confounders. The treatment protocol consisted of 100 mg of testosterone cypionate or a matching placebo administered via weekly intramuscular injections for a duration of 12 weeks. Of the initial cohort, 125 men completed the full study period. The trial commenced on May 13, 2019, and concluded on May 16, 2025. At baseline, the participants had a mean (SD) age of 68.6 (6.5) years. Regarding their original cancer pathology, 52 men (38%) had a Gleason score of 6 and 84 men (62%) had a Gleason score of 7, representing a cohort of patients with a generally favorable prognosis who are often the primary candidates for quality-of-life interventions in clinical practice.

Functional Gains and Sexual Health Outcomes

The researchers established sexual activity as the primary efficacy outcome, while secondary outcomes encompassed sexual desire, erectile function, psychological well-being, body composition, aerobic capacity, and physical function. Following the 12-week intervention, testosterone therapy significantly increased sexual activity more than placebo, demonstrating a between-group difference of 0.91 daily events (95% CI, 0.56-1.26; P < .001) after adjusting for age and the use of phosphodiesterase-5 inhibitors. Beyond the frequency of sexual encounters, the treatment group reported substantial improvements in subjective measures of sexual health. Specifically, testosterone therapy increased sexual desire and led to higher scores on the prostate cancer quality-of-life sexual domain compared to the placebo group. However, despite these gains in libido and activity, erectile function did not change significantly between the groups. For practicing physicians, this underscores that while testosterone replacement can restore sexual interest, it may not resolve the mechanical aspects of erectile dysfunction often associated with post-prostatectomy nerve damage. The clinical benefits of androgen replacement extended into the domains of psychological health and physical performance. Participants receiving testosterone cypionate experienced a decrease in negative affect (a clinical measure of distressed emotional states such as anger, contempt, or nervousness) more than those receiving placebo. Furthermore, the 100 mg weekly dosage led to measurable systemic improvements. Testosterone therapy significantly improved body composition, loaded stair-climbing power, and peak aerobic performance, measured as VO2 peak (the maximum rate of oxygen consumption during incremental exercise). These findings suggest that for men with low-grade prostate cancer and symptomatic hypogonadism, short-term testosterone replacement may effectively address both the sexual and metabolic sequelae of androgen deficiency.

Short-Term Safety and Clinical Limitations

The primary safety outcome of this phase 2 trial was the incidence of biochemical recurrence, which the researchers defined as a prostate-specific antigen (PSA) level of 0.2 ng/mL or higher. Monitoring this threshold is critical for clinicians managing post-prostatectomy patients, as any rise in PSA can signal the return of malignant cells. Throughout the 12-week intervention period, no participant in either the testosterone cypionate group or the placebo group experienced biochemical recurrence. This lack of PSA elevation suggests that, in the short term, a weekly 100 mg dose of testosterone cypionate does not stimulate residual prostatic tissue or occult micrometastases in this specific patient population. Despite these results, the researchers emphasized several clinical boundaries that must guide the application of these findings. The study was specifically designed as a proof-of-concept trial and was not long enough or large enough to evaluate clinical recurrence or long-term safety. Consequently, these data do not provide evidence regarding the oncological risks of testosterone replacement therapy beyond the three-month mark. Furthermore, the study population was highly selected, consisting only of men with organ-confined, low-grade disease (Gleason score of 6 or 7) and undetectable PSA levels for at least two years post-surgery. Clinicians should note that these findings do not apply to men with high-grade prostate cancer, nor do they extend to patients who have been treated with androgen deprivation therapy or radiation therapy. Because the trial focused exclusively on the post-radical prostatectomy setting for low-risk survivors, the safety profile of testosterone replacement in patients with more aggressive pathology or different primary treatments remains unestablished. The authors conclude that while these results justify the design of larger, long-term studies, the current evidence is limited to the short-term functional restoration of hypogonadal men with low-risk surgical histories.

References

1. Siegel RL, DeSantis C, Virgo KS, et al. Cancer treatment and survivorship statistics, 2012. CA A Cancer Journal for Clinicians. 2012. doi:10.3322/caac.21149

2. Robinson J, Banerjee I, Banerjee I. Testosterone Replacement in Prostate Carcinoma: A Systematic Review of an Emerging Paradigm and Therapeutic Potential. Cureus. 2025. doi:10.7759/cureus.94872

3. Lenfant L, Leon P, Cancel-Tassin G, et al. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer.. Urologic oncology. 2020. doi:10.1016/j.urolonc.2020.04.008

4. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.. International journal of impotence research. 2009. doi:10.1038/ijir.2008.31

5. García-Becerra CA, Arias-Gallardo MI, Juárez-García JE, et al. Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials.. International journal of impotence research. 2026. doi:10.1038/s41443-026-01237-4

6. Bhasin S, Travison TG, Pencina KM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.. JAMA network open. 2023. doi:10.1001/jamanetworkopen.2023.48692

7. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2018. doi:10.1210/jc.2018-00229